BLOG

endpoints

Looking to take advantage of ‘silenced’ enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

That’s the question a new biotech is aiming to answer, as SalioGen Therapeutics emerges from stealth Monday morning with a $20 million Series A. And they believe they’ve found a new delivery system that can more precisely deliver genes in vivo than the relatively large adeno-associated virus or CRISPR system: mammalian-derived enzymes.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}